CCRB Logo

Trial History Detail on 2011-02-08

CUHK_CCT00053

2005-09-09

Retrospective

None

Pfizer

Department of Medicine & Therapeutics, The Chinese University of Hong Kong

Boston Scientific

Leata Yeung

Department of Medicine & Therapeutics, The Chinese University of Hong Kong

2632 3841

leata@cuhk.edu.hk

CUHK

Prof Cheuk Man Yu

Department of Medicine & Therapeutics, The Chinese University of Hong Kong

2632 3136

cmyu@cuhk.edu.hk

CUHK

Atherosclerotic plaque burden reduction in Native and Intervened coronary arteries as well as in other Major arteries by High Dose ATorvastatin ThErapy-A double blind, randomized study (ANIMATE)

Atherosclerotic plaque burden reduction in Native and Intervened coronary arteries as well as in other Major arteries by High Dose ATorvastatin ThErapy-A double blind, randomized study (ANIMATE)

ANIMATE

HONG KONG

Yes

2003-07-03

Heart and Blood Vessel Diseases

Drug

Ischaemic Heart Disease Patients

6 Months

Atorvastatin 10 mg or 80 mg daily

Inclusion criteria: *Patient with established CAD indicated for PCI *Plasma LDL-cholesterol level >2.6mmol/L or clinically indicated for statin therapy

Exclusion criteria: *Significant renal failure that preclude coronary angiography and PCI *Significant left main CAD with significant risk to IVUS *Less than 6 months survival

>18

N/A

Both Male and Female

Interventional

Randomized

Dose comparison

Double-blind

Parallel

2003-07-03

140

Complete

• Atherosclerotic plaque burden by IVUS in the diseased native coronary artery that does not require PC1** • Atherosclerotic plaque burden by IVUS and restenosis by both IVUS and QCA for the degree of neointimal hyperplasia in the post-PCI coronary artery • Neointimal thickness of the carotid and brachial artery • Brachial artery dilatation in response to hyperaemia, i.e. the flow-depend dilatation as an indicator of endotheial function **only apply to the IVUS arm

• Coronary diameter and percentage stenosis by QCA • Cardiovascular event rate • Correlation of the degree of atherosclerotic plaque regression to symptoms and cardiovascular event rate

No

2009-11-27

ChiCTR-TRC-09000649

2010-05-04


Yes

Type Access Document Published On  
No documents yet.
  • Page 1 of 1.